Treatments for Primary Immune Thrombocytopenia: A Review.

Autor: Samson M; Emergency Medicine, University of Central Florida College of Medicine, Orlando, USA., Fraser W; Emergency Medicine, University of Central Florida College of Medicine, Orlando, USA., Lebowitz D; Emergency Medicine, University of Central Florida College of Medicine, Orlando, USA.
Jazyk: angličtina
Zdroj: Cureus [Cureus] 2019 Oct 06; Vol. 11 (10), pp. e5849. Date of Electronic Publication: 2019 Oct 06.
DOI: 10.7759/cureus.5849
Abstrakt: Immune thrombocytopenic purpura (ITP) is an autoimmune condition that affects nearly 1:10,000 people in the world. It is traditionally defined by a platelet count of less than 100 x 10 9 L, but treatment typically depends on symptomology rather than on the platelet count itself. For primary idiopathic ITP, corticosteroids have been the standard first-line of treatment for symptomatic patients, with the addition of intravenous immune globulin (IVIG) or Rh o (D) immune globulin (anti-RhD) for steroid-resistant cases. In cases of refractory or non-responsive ITP, second-line therapy includes splenectomy or rituximab, a monoclonal antibody against the CD20 antigen (anti-CD20). In patients who continue to have severe thrombocytopenia and symptomatic bleeding despite first- and second-line treatments, the diagnosis of "chronic refractory ITP" is appropriate, and third-line treatments are evaluated. This manuscript describes the efficacy of different treatment options for primary ITP and introduces the reader to various third-line options that are emerging as a means of treating chronic refractory ITP.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright © 2019, Samson et al.)
Databáze: MEDLINE
Externí odkaz: